AnaptysBio, Inc. (NASDAQ:ANAB) Receives $42.38 Average PT from Analysts
Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have received an average rating of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to […]
Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have received an average rating of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to […]
